Cancer vaccines for hepatocellular carcinoma: Future directions

Immunotherapy

Volumn 8, Issue 4, 2016, Pages 391-393

  Buonaguro, Franco M ^a   Buonaguro, Luigi ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

cancer vaccine; combinatorial strategies; hepatocellular carcinoma; immunotherapy; mutant antigens; tumor microenvironment

Indexed keywords

CANCER VACCINE; EPITOPE; TUMOR ANTIGEN;

ADAPTIVE IMMUNITY; CANCER IMMUNIZATION; CANCER PATIENT; GENE MUTATION; HUMAN; IMMUNOGENICITY; INNATE IMMUNITY; LIVER CELL CARCINOMA; PRIORITY JOURNAL; REVIEW; TH1 CELL; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT; ANIMAL; CARCINOMA, HEPATOCELLULAR; IMMUNOLOGY; IMMUNOTHERAPY; LIVER NEOPLASMS; MOLECULARLY TARGETED THERAPY; TRENDS;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CARCINOMA, HEPATOCELLULAR; HUMANS; IMMUNOTHERAPY; LIVER NEOPLASMS; MOLECULAR TARGETED THERAPY; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT;

EID: 84962560150     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt-2015-0018     Document Type: Review

References (20)

1. Villanueva A, Hernandez-Gea V, Llovet JM. Medical therapies for hepatocellular carcinoma: a critical view of the evidence. Nat. Rev. Gastroenterol. Hepatol. 10(1), 34-42 (2013).
2. Chan SL, Mok T, Ma BB. Management of hepatocellular carcinoma: beyond sorafenib. Curr. Oncol. Rep. 14(3), 257-266 (2012).
3. Greten TF, Wang XW, Korangy F. Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches. Gut 64(5), 842-848 (2015).
4. Buonaguro L, Petrizzo A, Tagliamonte M, Tornesello ML, Buonaguro FM. Challenges in cancer vaccine development for hepatocellular carcinoma. J. Hepatol. 59(4), 897-903 (2013).
5. den Brok MH, Sutmuller RP, van der Voort R, et al. In situ tumor ablation creates an antigen source for the generation of antitumor immunity. Cancer Res. 64(11), 4024-4029 (2004).
6. Jansen MC, van HR, Schoots IG, et al. Cryoablation induces greater inflammatory and coagulative responses than radiofrequency ablation or laser induced thermotherapy in a rat liver model. Surgery 147(5), 686-695 (2010).
7. Maiti R. Metronomic chemotherapy. J. Pharmacol. Pharmacother. 5(3), 186-192 (2014).
8. Hodge JW, Ardiani A, Farsaci B, Kwilas AR, Gameiro SR. The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors. Semin. Oncol. 39(3), 323-339 (2012).
9. Ge Y, Domschke C, Stoiber N, et al. Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome. Cancer Immunol. Immunother. 61(3), 353-362 (2012).
10. Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin. Cancer Res. 11(18), 6713-6721 (2005).
11. Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161(2), 205-214 (2015).
12. Bertino G, Demma S, Ardiri A, et al. The immune system in hepatocellular carcinoma and potential new immunotherapeutic strategies. Biomed. Res. Int. 731469 (2015).
13. El Ansary M, Mogawer S, Elhamid SA, et al. Immunotherapy by autologous dendritic cell vaccine in patients with advanced HCC. J. Cancer Res. Clin. Oncol. 139(1), 39-48 (2013).
14. Singh-Jasuja H, Emmerich NP, Rammensee HG. The Tubingen approach: identification, selection, and validation of tumor-Associated HLA peptides for cancer therapy. Cancer Immunol. Immunother. 53(3), 187-195 (2004).
15. Heidenreich R, Jasny E, Kowalczyk A, et al. A novel RNAbased adjuvant combines strong immunostimulatory capacities with a favorable safety profile. Int. J. Cancer 137, 372-384 (2015).
16. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science 348(6230), 69-74 (2015).
17. Castle JC, Kreiter S, Diekmann J, et al. Exploiting the mutanome for tumor vaccination. Cancer Res. 72(5), 1081-1091 (2012).
18. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science 339(6127), 1546-1558 (2013).
19. Greten TF, Forner A, Korangy F, et al. A Phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma. BMC Cancer 10, 209 (2010).
20. Sawada Y, Yoshikawa T, Shimomura M, Iwama T, Endo I, Nakatsura T. Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes. Int. J. Oncol. 46(1), 28-36 (2015).